[HTML][HTML] Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer
Although precision medicine has had a mixed impact on the clinical management of patients
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …
Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics
Cell-free DNA (cfDNA) in the circulating blood plasma of patients with cancer contains
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
tumour-derived DNA sequences that can serve as biomarkers for guiding therapy, for the …
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Immune checkpoint blockade (ICB) provides clinical benefit to a subset of patients with
cancer. However, existing biomarkers do not reliably predict treatment response across …
cancer. However, existing biomarkers do not reliably predict treatment response across …
Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial
In patients with previously treated metastatic uveal melanoma, the historical 1 year overall
survival rate is 37% with a median overall survival of 7.8 months. We conducted a …
survival rate is 37% with a median overall survival of 7.8 months. We conducted a …
Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition
Although treatment of non-small cell lung cancer (NSCLC) with immune checkpoint
inhibitors (ICIs) can produce remarkably durable responses, most patients develop early …
inhibitors (ICIs) can produce remarkably durable responses, most patients develop early …
[HTML][HTML] Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial
S Ren, J Chen, X Xu, T Jiang, Y Cheng, G Chen… - Journal of Thoracic …, 2022 - Elsevier
Introduction Camrelizumab, a humanized immunoglobulin G4-κ monoclonal antibody
against programmed cell death protein 1, has exhibited antitumor activity and tolerability …
against programmed cell death protein 1, has exhibited antitumor activity and tolerability …
Circulating tumor DNA and liquid biopsy in oncology
Techniques for analyzing circulating tumor DNA (ctDNA) to detect, characterize and monitor
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …
cancer have matured rapidly. An increasing body of clinical evidence is demonstrating the …
The lung microenvironment: an important regulator of tumour growth and metastasis
NK Altorki, GJ Markowitz, D Gao, JL Port… - Nature Reviews …, 2019 - nature.com
Lung cancer is a major global health problem, as it is the leading cause of cancer-related
deaths worldwide. Major advances in the identification of key mutational alterations have led …
deaths worldwide. Major advances in the identification of key mutational alterations have led …
Immune-checkpoint inhibition for resectable non-small-cell lung cancer—Opportunities and challenges
G Mountzios, J Remon, LEL Hendriks… - Nature Reviews …, 2023 - nature.com
Therapeutic strategies harnessing the immune system to eliminate tumour cells have been
successfully used for several cancer types, including in patients with advanced-stage non …
successfully used for several cancer types, including in patients with advanced-stage non …
Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade
The utility of circulating tumor DNA (ctDNA) as a biomarker in patients with advanced
cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n= 978) …
cancers receiving immunotherapy is uncertain. We therefore analyzed pretreatment (n= 978) …